Head Office
Novartis International AG
CH-4002 Basel
Switzerland
+41 61 324 11 11
+41 61 324 80 01
Monday - Friday,
8:30 - 17:00, GMT+1
(Central European Time)
Novartis International AG
Investor Relations
P.O. Box
CH-4002 Basel
Switzerland
+41 61 324 79 44
investor.relations@novartis.com
Global Media Relations
Eric Althoff
Basel, Switzerland
+41 61 324 7999
eric.althoff@novartis.com
Report a suspected side effect (also known as an adverse event) related to a Novartis Pharmaceutical drug or a Novartis Vaccine.
The Global Reporting Initiative (GRI) is a multi-stakeholder process that aims to develop a common global framework for sustainability reporting. The objective is to elevate sustainability reporting to the same level of rigor and credibility expected of financial reporting.
The 2011 Novartis GRI report uses the GRI G3 Sustainability Reporting Guidelines at an application level of A+, checked and confirmed by the GRI.
© 2013 Novartis AG Terms of usePrivacy policy Sitemap
